Treatment of adult short bowel syndrome patients with teduglutide.

Abstract:

INTRODUCTION:Parenteral support is lifesaving in short bowel syndrome patients with intestinal failure (SBS-IF), who are unable to compensate for their malabsorption by metabolic or pharmacologic adaptation. Mutually, the symptoms of SBS-IF and the inconveniences and complications in relation to parenteral support may cause impairment of the quality of life of SBS-IF patients. Conventional treatments include dietary manipulations, oral rehydration solutions, antidiarrheal and antisecretory treatments. However, the evidence base for these interventions is limited, and treatments improving structural and functional integrity of the remaining intestine are desired. Teduglutide , an analog of glucagon-like peptide 2, improves intestinal rehabilitation by promoting mucosal growth and possibly by inhibiting gastric emptying and secretion, which in turn reduces intestinal losses and promotes intestinal absorption. AREAS COVERED:This paper reviews the following findings: in a 3-week, Phase II balance study, teduglutide reduced diarrhea by ∼ 700 g/day and fecal energy losses by ∼ 0.8 MJ/day, and in a randomized, placebo-controlled, 24-week, Phase III study, corresponding reductions in the need for parenteral support were obtained. EXPERT OPINION:Teduglutide seems to be safe and well-tolerated and demonstrates restoration of structural and functional integrity of the remaining intestine with significant intestinotrophic and proabsorptive effects, facilitating a reduction in diarrhea and an equivalent reduction in the need for parenteral support in SBS-IF patients.

authors

Nørholk LM,Holst JJ,Jeppesen PB

doi

10.1517/14656566.2012.644787

subject

Has Abstract

pub_date

2012-02-01 00:00:00

pages

235-43

issue

2

eissn

1465-6566

issn

1744-7666

journal_volume

13

pub_type

杂志文章,评审
  • Varicella zoster: an update on current treatment options and future perspectives.

    abstract:INTRODUCTION:Varicella zoster virus is a highly contagious virus that causes a primary infection known as varicella (chickenpox) that may reactivate years later to cause herpes zoster (HZ or shingles). After shingles heal, patients may develop post-herpetic neuralgia (PHN), neuropathic pain syndrome that can cause sign...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.860443

    authors: Kim SR,Khan F,Ramirez-Fort MK,Downing C,Tyring SK

    更新日期:2014-01-01 00:00:00

  • Abaloparatide Comparator Trial In Vertebral Endpoints (ACTIVE) confirms that abaloparatide is a valuable addition to the armamentarium against osteoporosis.

    abstract::The recently published Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) assessed the efficacy and safety of abaloparatide (80 µg daily subcutaneous) (ABL) vs placebo during 18 months, in postmenopausal osteoporosis. Teriparatide (20 µg daily subcutaneous) (TPD) was used as an open label active comparator...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1080/14656566.2017.1395021

    authors: Reginster JY,Al Daghri NM,Bruyere O

    更新日期:2017-12-01 00:00:00

  • Antipsychotic medication: effects on regulation of glucose and lipids.

    abstract::Since the introduction of chlorpromazine in the 1950s, antipsychotics have been used for the treatment of schizophrenia. The phenothiazines were followed by the butyrophenones, particularly haloperidol. With all the movement disorder side effects of these medications (extrapyramidal syndrome, akathisia, tardive dyskin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2.10.1571

    authors: Kato MM,Goodnick PJ

    更新日期:2001-10-01 00:00:00

  • Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies.

    abstract:INTRODUCTION:Immune-checkpoint inhibitor (ICPI) drugs, which include antibodies against CTLA-4, PD-1 and PD-L1, have been shown to induce durable complete responses in a proportion of patients with particular efficacy demonstrated in both the first line and refractory setting in advanced NSCLC and melanoma. However, th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1369956

    authors: Flynn MJ,Larkin JMG

    更新日期:2017-10-01 00:00:00

  • Challenges and treatment options for rheumatoid arthritis during pregnancy.

    abstract:INTRODUCTION:Rheumatoid arthritis (RA) can spontaneously improve during pregnancy. However, a considerable proportion of patients can experience a flare and high disease activity has been associated with an increased risk of adverse pregnancy outcome. Thus, the treatment of RA in pregnant women should be selected takin...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2016.1197204

    authors: Gerosa M,Schioppo T,Meroni PL

    更新日期:2016-08-01 00:00:00

  • Radiocontrast-induced nephropathy and percutaneous coronary intervention: a review of preventive measures.

    abstract::Injectable and absorbable contrast media for the use in radiology, all of which contains iodine as an essential component, has been, and continues to be, one of the main sources of agents which cause hospital-acquired renal failure. Although numerous methods have been explored to prevent renal contrast damage, radioco...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.639

    authors: Mintz EP,Gruberg L

    更新日期:2003-05-01 00:00:00

  • Lipid pharmacotherapy for treatment of atherosclerosis.

    abstract:INTRODUCTION:For more than two decades, lowering levels of low-density lipoprotein cholesterol has formed the cornerstone of management of patients with atherosclerotic cardiovascular disease. The substantial residual risk of clinical events in patients treated with statin therapy highlights the need to develop more ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2014.904287

    authors: Nicholls SJ,Pisaniello AD,Kataoka Y,Puri R

    更新日期:2014-06-01 00:00:00

  • Erectile dysfunction, cardiovascular diseases and depression: interaction of therapy.

    abstract::Several studies have revealed the intimate associations between erectile dysfunction (ED), ischemic heart disease (IHD) and depression. Whether the physicians should also screen for the other two components when a patient presents with one component of this triad is still an important question to be answered. These th...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903089326

    authors: El-Sakka AI,Shamloul R,Yassin AA

    更新日期:2009-09-01 00:00:00

  • The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice.

    abstract:INTRODUCTION:Acute diarrhea remains a major problem in children and is associated with substantial morbidity, mortality and costs. While vaccination against rotavirus could reduce the burden of the disease, the persistent impact of intestinal infections requires effective treatment in adjunct to oral rehydration soluti...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2011.634800

    authors: Guarino A,Dupont C,Gorelov AV,Gottrand F,Lee JK,Lin Z,Lo Vecchio A,Nguyen TD,Salazar-Lindo E

    更新日期:2012-01-01 00:00:00

  • Miconazole, a pharmacological barrier to skin fungal infections.

    abstract:INTRODUCTION:Miconazole (MCZ) is a time-honored antifungal of the imidazole class. MCZ exerts a multipronged effect on fungi. It inhibits the cytochrome P450 complex, including the 14α-demethylase enzyme required for ergosterol biosynthesis, in fungal cell membranes. In addition, intracellular accumulation of toxic met...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.687047

    authors: Piérard GE,Hermanns-Lê T,Delvenne P,Piérard-Franchimont C

    更新日期:2012-06-01 00:00:00

  • An evaluation of baricitinib as a therapeutic option for adult patients with moderate to severe atopic dermatitis.

    abstract:INTRODUCTION:Moderate-to-severe AD burdens a large proportion of AD patients and may represent an inadequacy of treatment options available for resistant disease. AREAS COVERED:This review provides an overview of the therapies for moderate-to-severe AD in late-stage development and in the clinic, and focuses on barici...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,多中心研究,评审

    doi:10.1080/14656566.2020.1739268

    authors: Mendes JT,Balogh EA,Strowd LC,Feldman SR

    更新日期:2020-06-01 00:00:00

  • An economic commentary on the occurrence and control of HIV/AIDS in developing countries: special reference to India.

    abstract::HIV infection has a complex relationship with poverty, but affects both the rich and poor. HIV/AIDS represents the deadliest emergency and the greatest social, economic and health crisis of modern times. The HIV pandemic affects developed and developing countries differently, with up to 95% of new HIV infections now o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 社论

    doi:10.1517/14656566.7.18.2447

    authors: Muniyandi M,Ramachandran R,Balasubramanian R

    更新日期:2006-12-01 00:00:00

  • Vortioxetine: a New Treatment for Major Depressive Disorder.

    abstract:INTRODUCTION:Vortioxetine is a structurally novel medication that has recently been approved for treatment of major depressive disorder (MDD). This medication is a serotonin reuptake inhibitor that also has a number of other potentially relevant effects on serotoninergic receptors, which may differentiate the drug's ef...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2016.1133588

    authors: Connolly KR,Thase ME

    更新日期:2016-01-01 00:00:00

  • Etravirine: the renaissance of non-nucleoside reverse transcriptase inhibitors.

    abstract:BACKGROUND:Etravirine is the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to be active against human immunodeficiency virus with NNRTI mutations. OBJECTIVE:To understand the unique features of etravirine and to evaluate its safety, efficacy, and optimal use. METHODS:The structure and the mechanism of ...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章

    doi:10.1517/14656560802489569

    authors: Jayaweera DT,Espinoza L,Castro J

    更新日期:2008-12-01 00:00:00

  • Update on pharmacotherapy of myoclonic seizures.

    abstract:INTRODUCTION:Myoclonic seizures are brief, involuntary muscular jerks arising from the central nervous system that can occur in different epilepsy syndromes, including idiopathic generalized epilepsies or the most severe group of epileptic encephalopathies. Valproate is commonly the first choice alone or in combination...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2017.1280459

    authors: Striano P,Belcastro V

    更新日期:2017-02-01 00:00:00

  • Everolimus: an immunosuppressive agent in transplantation.

    abstract::Everolimus is a novel immunosuppressive agent related to sirolimus. It is a proliferation signal inhibitor with an improved pharmacokinetic profile and bioavailability compared with sirolimus. Everolimus has been shown to be as effective as mycophenolate mofetil in reducing acute rejection in renal transplantation. In...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.7.10.1347

    authors: Patel JK,Kobashigawa JA

    更新日期:2006-07-01 00:00:00

  • Pharmacotherapy options in pulmonary alveolar proteinosis.

    abstract:INTRODUCTION:Pulmonary alveolar proteinosis (PAP) is a heterogeneous group of rare diseases characterized by the abnormal production and impaired degradation of pulmonary surfactant as a result of malfunctioning of alveolar macrophages. This is due to the downstream dysregulation of the GM-CSF pathway, which can be cau...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2020.1757650

    authors: Antoniu SA,Rajnoveanu R,Grigore M,Antohe I

    更新日期:2020-08-01 00:00:00

  • Colesevelam HCl: a non-systemic lipid-altering drug.

    abstract::Colesevelam HCl (WelChol, Sankyo Pharmaceuticals Inc.) is a bile acid sequestrant polymer, which has been shown to significantly lower low density lipoprotein cholesterol and favourably affect high-density lipoprotein cholesterol blood levels in monotherapy and in combination with statins (HMG-CoA reductase inhibitors...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.5.779

    authors: Bays H,Dujovne C

    更新日期:2003-05-01 00:00:00

  • Efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring: a post hoc analysis with single-day treatment.

    abstract:OBJECTIVE:To compare the efficacy of mitiglinide and sitagliptin, alone or in combination, on postprandial excursion and glycemic variability assessed by continuous glucose monitoring (CGM) in a single-day treatment setting. METHODS:This was a post hoc analysis of a randomized crossover study comparing the efficacy of...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,随机对照试验

    doi:10.1517/14656566.2015.1035646

    authors: Baek JH,Jin SM,Kaku K,Jung JA,Kim JR,Ko JW,Kim MJ,Lee SY,Huh WS,Kim JH

    更新日期:2015-06-01 00:00:00

  • Combination strategies for pain management.

    abstract::At least two factors relating to pain management using oral analgesics suggest that combination strategies merit consideration: many pains arise from more than one physiological cause and current analgesics have adverse effect profiles that might be reduced by combination with another agent in smaller doses or with le...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.4.10.1697

    authors: Raffa RB,Clark-Vetri R,Tallarida RJ,Wertheimer AI

    更新日期:2003-10-01 00:00:00

  • Treating obesity in patients with cardiovascular disease: the pharmacotherapeutic options.

    abstract:INTRODUCTION:Obesity is a growing health problem that has numerous comorbidities, including cardiovascular disease (CVD). The multi-disciplinary treatment of obesity now includes the use of pharmacotherapy. When treating patients with obesity and CVD, certain medications may be more appropriate than others. AREAS COVE...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2018.1561867

    authors: Andrew CA,Saunders KH,Shukla AP,Aronne LJ

    更新日期:2019-04-01 00:00:00

  • Alpha-1 antitrypsin (AAT) deficiency - what are the treatment options?

    abstract::Alpha-1 antitrypsin (AAT) deficiency is an under-recognized genetic condition that predisposes to liver disease and early-onset emphysema. Although AAT is mainly produced in the liver, its main function is to protect the lung against proteolytic damage from neutrophil elastase. The most common mutation responsible for...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560903300111

    authors: Modrykamien A,Stoller JK

    更新日期:2009-11-01 00:00:00

  • Several options for antiviral treatment trials in multiple sclerosis--but which targets should be selected?

    abstract::Involvement of viruses in the pathogenesis of multiple sclerosis (MS) is a long-lived hypothesis, which is has not yet been proven nor refuted. This is partly due to difficulties in the evaluation of diagnostic findings on persistent infections by common viruses such as herpesviruses and endogenous retroviruses. Progr...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.1.6.1087

    authors: Bergström T

    更新日期:2000-09-01 00:00:00

  • Overview of the [corrected] travoprost /timolol BAK-free fixed combination.

    abstract:INTRODUCTION:Glaucoma is the second leading cause of blindness globally, representing a significant public health concern. More than 60 million people are affected by glaucoma worldwide; as this population ages, the number is expected to increase. Glaucoma is a collection of heterogeneous diseases sharing common clinic...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.662485

    authors: Konstas AG,Quaranta L,Realini T

    更新日期:2012-04-01 00:00:00

  • MP29-02: a breakthrough for the treatment of allergic rhinitis.

    abstract:INTRODUCTION:Allergic rhinitis (AR) can be challenging to treat. For many patients, current therapies (including multiple therapies) provide insufficient symptom relief. There is, therefore, a clear unmet medical need for a new and more effective AR treatment option. MP29-02 ( Dymista ) is a novel intranasal formulatio...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2013.828693

    authors: Bernstein JA

    更新日期:2013-10-01 00:00:00

  • Chemoradiotherapy for lung cancer.

    abstract::Chemoradiotherapy is a standard treatment for both unresectable locally advanced non-small cell lung cancer and limited-stage small cell lung cancer. Cisplatin-based chemotherapy with concurrent thoracic radiotherapy yields a 5-year survival rate of approximately 15% for patients with unresectable locally advanced non...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.6.16.2793

    authors: Ohe Y

    更新日期:2005-12-01 00:00:00

  • Neuraminidase inhibitors as a strategy for influenza treatment: pros, cons and future perspectives.

    abstract::Introduction: Influenza represents a major public health threat worldwide. Implementation of good personal health and hygiene habits, together with vaccination, is the most effective tools to reduce influenza burden both in community and in healthcare setting. However, achieving adequate vaccination rates is challengi...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1626824

    authors: Bassetti M,Castaldo N,Carnelutti A

    更新日期:2019-10-01 00:00:00

  • Pharmacotherapy of obstructive sleep apnea.

    abstract:INTRODUCTION:Obstructive sleep apnea syndrome is a common public health problem in the general population. The important health-related consequences of obstructive sleep apnea include cardiovascular disorders, such as myocardial infarction and hypertension, stroke, sudden death and difficult blood sugar control related...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656566.2012.666525

    authors: Lin CM,Huang YS,Guilleminault C

    更新日期:2012-04-01 00:00:00

  • Emerging therapies for ionizing radiation-associated skin field carcinogenesis.

    abstract:BACKGROUND:Radiodermatitis in its acute and chronic presentations represents a set of specific adverse effects resulting from ionizing radiations. Skin-field cancerization is another condition associated to or independent of clinically recognizable radiodermatitis. This condition leads to the risk of later occurrence o...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1517/14656560902754060

    authors: Piérard GE,Piérard-Franchimont C,Paquet P,Quatresooz P

    更新日期:2009-04-01 00:00:00

  • Treatment of classical Hodgkin's lymphoma in children and adolescents.

    abstract:INTRODUCTION:The treatment of classical Hodgkin lymphoma (cHL) in children is a story of success. Nowadays, more than 90% of patients are cured and overall survival is nearly 100% at 5 years. Efforts have been made to avoid related effects of therapies; therefore, children are treated using different chemotherapy schem...

    journal_title:Expert opinion on pharmacotherapy

    pub_type: 杂志文章,评审

    doi:10.1080/14656566.2019.1606212

    authors: Gómez-Almaguer D,González-Llano O,Jiménez-Antolinez V,Gómez-De León A

    更新日期:2019-07-01 00:00:00